Vestibular migraine (VM) is one of the most common vestibular disorders, affecting 1.0% to 2.7% of the general population1, 7% of patients with definite migranous vertigo in dizziness clinics2, as well as 10.3% of VM patients in headache clinics3; 65% to 85% of VM patients are female1. Despite the relative prevalence of vestibular migraine, evidence-based medicine remains scarce. Two Cochrane reviews published in 2023 found that there is almost no evidence to support the use of medications for the acute treatment or preventive treatment of VM4,5.
Calcitonin gene-related peptide (CGRP) has been established as an excellent target for the treatment of migraine. Animal studies suggest a link between CGRP and vestibular disorders. A prospective observational cohort study found that monoclonal antibodies targeting CGRP receptors and ligands were very effective for vestibular migraine (VM), with 90% of participants experiencing at least a 50% reduction in vertigo attacks6. A small-scale prospective randomized controlled trial showed that a monoclonal antibody targeting a CGRP ligand significantly reduced the number of dizziness days per month in VM patients compared to placebo7. The efficacy of CGRP small molecule antagonists for the preventive and acute treatment of migraines has been widely recognized8,9. Therefore, we speculate that Rimegepant is effective for the preventive and acute treatment of vestibular migraine.
By focusing on a large sample RCT, our study can offer new evidence-based treatment options for patients with vestibular migraine. This is crucial, as many patients with vestibular migraine may not respond well to conventional migraine treatments. Our findings could guide clinicians in choosing more effective therapeutic strategies.
Specifically in acute treatment of vestibular migraine, triptans have failed to show superiority when compared to placebo in treatment vestibular migraine symptoms10. Prochlorperazine, a vestibular sedative, is widely used for acute treatment of vestibular migraine but is known to chronify symptoms11. Should rimegepant demonstrate superiority to placebo in this study, rimegepant could potentially become the first-line treatment for vestibular migraine across the world.

Start Date01 Apr 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT06641466

/ Not yet recruitingPhase 3

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Start Date24 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06728345

/ Not yet recruitingNot ApplicableIIT

The Real-world Study of Rimegepant for the Preventive Treatment in Female Migraine Patients

The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings :
1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12
2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12

Start Date01 Dec 2024

Sponsor / Collaborator

The First Affiliated Hospital of Soochow University

100 Clinical Results associated with Rimegepant Sulfate

100 Translational Medicine associated with Rimegepant Sulfate

100 Patents (Medical) associated with Rimegepant Sulfate

193

Literatures (Medical) associated with Rimegepant Sulfate

31 Dec 2024·Journal of Medical Economics

Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK

Article

Author: Pawinski, Robert ; Powell, Lauren C. ; L’Italien, Gil J. ; Tran, Thang ; Johnston, Karissa ; Popoff, Evan ; Large, Sam ; Jenkins, Aaron ; Ahern, Aideen

AIMSMigraine is the most common disabling headache disorder and is characterized by recurrent throbbing head pain and symptoms of photophobia, phonophobia, nausea, and vomiting. Rimegepant 75 mg, an oral lyophilisate calcitonin gene-related peptide antagonist, is the first treatment approved for both the acute and preventative treatment of migraine, and the first acute therapy approved in over 20-years. The objective was to assess the cost-utility of rimegepant compared with best supportive care (BSC) in the UK, for the acute treatment of migraine in the adults with inadequate symptom relief after taking at least 2 triptans, or for whom triptans are contraindicated or not tolerated.MATERIALS AND METHODSA de novo model was developed to estimate incremental costs and quality-adjusted life years (QALYs), structured as a decision tree followed by Markov model. Patients received rimegepant or BSC for a migraine attack and were assessed for response (pain relief at 2-h). Responders and non-responders followed different pain trajectories over 48-h cycles. Non-responders discontinued treatment while responders continued treatment for subsequent attacks, with a proportion discontinuing over time. Data sources included a post-hoc pooled analysis of the phase 3 acute rimegepant trials (NCT03235479, NCT03237845, NCT03461757), and a long-term safety study (NCT03266588). The analysis was conducted from the perspective of the UK National Health Service and Personal Social Services over a 20-year time horizon.RESULTSRimegepant resulted in an incremental cost-utility ratio (ICUR) of £10,309 per QALY gained vs BSC, which is cost-effectiveness at a willingness to pay threshold of £30,000/QALY. Rimegepant generated +0.44 incremental QALYs and higher incremental lifetime costs (£4,492). Improved QALYs for rimegepant were a result of less time spent with severe and moderate headache pain.CONCLUSIONThis study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.

01 Dec 2024·Expert Review of Neurotherapeutics

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence

Review

Author: Edvinsson, Lars

INTRODUCTIONRimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine.AREAS COVEREDA brief overview of migraine, the pharmacokinetics of rimegepant, and the mechanism of action of rimegepant are provided. Evidence evaluating rimegepant as an acute or preventive treatment of migraine is then summarized in more detail, based on a literature search for full-length publications related to clinical or real-world use of rimegepant.EXPERT OPINIONSeveral clinical trials established rimegepant as a safe and effective treatment (acute and preventive) of migraine in adults. There are few head-to-head studies with other migraine treatments to determine relative efficacy. However, the favorable safety profile of rimegepant makes it appropriate for many patients, particularly those with contraindication, intolerance, or inadequate response to other classes of standard-of-care migraine treatments. Additional studies on the efficacy and cost-effectiveness relative to other treatments may further define the role of rimegepant in migraine treatment.

01 Dec 2024·CNS & Neurological Disorders - Drug Targets

Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis

Review

Author: Datusalia, Ashok Kumar ; Sumadhura, Bommaraju ; Singh, Pooja ; Sharma, Ruchika ; Kumar, Anoop ; Ponnada, Rakesh Kumar

Background:Recently, US Food and Drug Administration (FDA) has approved calcitonin gene-related peptide receptor antagonists (rimegepant, and ubrogepant), and selective serotonin receptor agonists (lasmiditan) in the management of migraine. However, the exact safety and efficacy profile of these drugs is unclear so far.Methods:The study’s primary objective was to determine the exact safety and efficacy profile. The overall estimate was calculated in terms of risk ratios using a suitable model. The subgroup analysis was also performed to check the effect of individual drugs on the outcome, whereas sensitivity analysis was performed to check the effects of outliers on the outcome. All the analyses were performed using Rev Man 5. The drugs have shown significant improvement in efficacy parameters (pain freedom, most bothersome symptoms, phonophobia, nausea, and photophobia).Results:The subgroup analysis results have shown significant improvement in all efficacy parameters in the rimegepant and ubrogepant groups. The effect of ubrogepant on safety parameters was found to be non-significant, indicating a better safety profile of ubrogepant than lasmiditan.Conclusion:The sensitivity analysis results have shown no effect of outliers on the efficacy parameters. Based on the available evidence, recently approved drugs are effective in the treatment of migraine, however, associated with few adverse drug reactions.

News (Medical) associated with Rimegepant Sulfate

30 Dec 2024

·www.prnewswire.com

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. "We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized myasthenia gravis and CIDP patients," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We look forward to VYVDURA being a new treatment option for an even broader number of patients in Japan." The MHLW approval is based on the ADHERE Study, the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with VYVDURA, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. Ninety-nine percent of trial participants elected to participate in the ADHERE+ open-label extension. The safety results were generally consistent with the known safety profile of VYVDURA in previous clinical studies and real-world use. VYVDURA was also approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was designated as an Orphan Drug for the treatment of CIDP by the MHLW. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugClinical Result

30 Oct 2024

·www.pharmaceutical-technology.com

Pfizer boasts over 30% increase in Q3 revenues against previous year

Pfizer CEO Dr Albert Bourla presided over an exceptional Q3 amid financial decline and pressure from investor Starboard Value. Credit: Ververidis Vasilis / Shutterstock. Pfizer has reported strong revenues in its latest earnings report, noting increased revenues over Q3 2023 largely due to sales from the company’s Covid-19 drugs Paxlovid and Comirnaty. In the 29 October report, Pfizer stated overall revenues in Q3 2024 had risen by 31% compared to the same quarter in the previous year, amounting to an additional $4.3bn. Of the total $17.7bn in Q3 revenues, $2.7bn and $1.4bn were derived from sales of Paxlovid and Comirnaty, respectively, which together accounted for almost half of the company’s year-over-year growth. The robust Q3 report did little to affect share price, although traded share volume rose to a level unseen since the company acquired Seagen in December 2023. Pfizer’s market cap is currently $161bn. This month has also seen disruption to the company’s management, as activist hedge fund Starboard Value took a $1bn stake in Pfizer, equivalent to 0.6% of the company at the time of purchase. Aiming to steer a turnaround in Pfizer’s fortunes, Starboard accused company executives of “ coercive conduct ” against former CEO Ian Read and former CFO Frank D’Amelio who retracted support after initially supporting the fund’s plans. In the Q3 conference call, Pfizer CEO Albert Bourla stated: “While we agree with some of the points [Starboard] raised, we have vastly different views on many others.” See Also: How a patient helped shape a treatment for rare skin disorder ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing He noted common dissatisfaction with shareholder return, but disagreed with Starboard’s challenge of Pfizer’s capital deployment, saying the company’s deals with Seagen and BioNTech “have been transformational for Pfizer”. Nonetheless, Bourla said some changes have been made at Pfizer this year to address Starboard’s such as separating US and international business and restructuring company management. The 31% Q3 growth over Q3 2023 was in sharp contrast to the overall growth of 2% for the first nine months of 2024 compared to those of 2023. Consequently, Pfizer has adjusted its financial guidance, raising projected revenues for 2024 to between $61bn and $64bn, up $1.5bn from estimates made in the company’s Q2 statement. This includes estimated sales of $5bn and $5.5bn from Comirnaty and Paxlovid, respectively, bringing the full year’s expected growth to 9% to 11% over 2023. Pfizer also attributed upticks in 2024 Q3 revenue to $854m in quarterly sales due to its acquisition of Seagen. Alongside this were increased operational revenues of 9% for Eliquis (apixaban), 28% for Xtandi (enzalutamide), 45% for Vydura (rimegepant sulfate), and 63% for Pfizer’s Vyndagel family (tafamidis) against equivalent quarterly revenues the previous year. Some drug-specific revenues did see decreases. Namely, revenues for Xeljanz (tofacitinib citrate) were down 35% and decreased by 12% for Ibrance (palbociclib) compared to Q3 2023. Drops in sales were attributed to label changes, lowered US net price, and expiry of exclusivity in Canada for Xeljanz, as well as competitive pressure and international price decreases for Ibrance. Bourla and Pfizer CFO David Denton gave statements attributing the company’s strong Q3 in part to ongoing cost reduction efforts and heightened demand for Paxlovid during the recent wave of Covid-19.

AcquisitionFinancial StatementIPO

19 Sep 2024

·www.fiercepharma.com

New migraine drugs less effective than previous generation of triptan meds: BMJ study

A meta-analysis of 137 trials of migraine drugs indicates that the newest class of treatments are less effective than the previous generation of triptan drugs in relieving acute headaches. A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.What's more, the newer drugs are no more effective in treating migraines than traditional headache remedies such as Tylenol, ibubrofen and aspirin, according to The BMJ's analysis.The study, a meta-analysis of 137 trials that together enrolled nearly 90,000 patients, indicates that the most effective treatments for migraine come from the triptan class. In head-to-head comparisons of the 17 drugs covered in the study, triptans demonstrated the best efficacy within 2 hours of use, led by eletriptan, which also delivered the best-sustained relief over 24 and 48 hours, according to the analysis.Eletriptan was brought to the market by Pfizer in 2002 and sold under the brand name Relpax. The next most effective medicines in providing relief at 2 hours were the following triptans (in order of performance): rizatriptan, sumatriptan and zolmitriptan. Rizatriptan is sold by Organon as Maxalt. GSK sells sumatriptan as Imitrex and AstraZeneca markets zolmitriptan as Zomig.“Triptans are currently widely underused, and access to the most effective triptans should be promoted globally and international guidelines updated accordingly,” the authors wrote. The BMJ analysis also concluded that the newest class of migraine treatments—which are called calcitonin gene-related peptide receptor (CGRP) antagonists—should only be used after traditional headache meds.“While the recent introduction of lasmiditan (Reyvow), rimegepant (Nurtec), and ubrogepant (Ubrelvy) has expanded options for the acute treatment of migraine, the high cost of these newer drugs, along with the substantial adverse effects of lasmiditan, suggest their use as third-line options, after the less expensive, similarly efficacious, second-line options," the authors wrote.While the BMJ study focused on acute treatment of migraines, new CGRP treatments have also been approved as preventatives. Nurtec pills, for example, were approved in 2021 for use every other day to ward off potential migraines. Much hope has been pinned on the effectiveness of CGRP drugs. In 2022, Pfizer spent $11.6 billion in a buyout of Biohaven to gain Nurtec, which rolled up sales of $928 million last year. Meanwhile, Ubrelvy, which was approved in 2019, generated $815 million in sales.Several other CGRPs—all approved in 2018 for the prevention of migraines—also remain formidable. Eli Lilly’s Emgality generated $678 million in sales last year, while Teva’s Ajovy pulled in $435 million and Amgen’s Aimovig collected $303 million. Besides those drugs, Lundbeck's Vyepti won approval in 2020 and generated about $250 million last year.

Drug ApprovalAcquisitionClinical Result

100 Deals associated with Rimegepant Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Rimegepant Sulfate	N02C	DB12457

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	US	Pfizer Inc.	27 Feb 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine Disorders	NDA/BLA	CN	Baiaoxin Management (Shanghai) Co., Ltd.	06 Sep 2022
Migraine Disorders	NDA/BLA	CN	Catalent U.K. Swindon Zydis Ltd.	06 Sep 2022
Chronic rhinosinusitis with nasal polyps	Phase 3	US	Pfizer Inc.	17 Feb 2022
Migraine With Aura	Phase 3	US	Pfizer Inc.	28 Apr 2021
Migraine With Aura	Phase 3	ES	Pfizer Inc.	28 Apr 2021
Migraine With Aura	Phase 3	PL	Pfizer Inc.	28 Apr 2021
Acute migraine	Phase 3	CN	Bioshin Ltd.	22 Oct 2020
Acute migraine	Phase 3	CN	Pfizer Inc.	22 Oct 2020
Acute migraine	Phase 2	KR	Bioshin Ltd.	22 Oct 2020
Acute migraine	Phase 2	KR	Pfizer Inc.	22 Oct 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03266588 (phase II/III safety study of rimegepant, Pubmed \| Pain Ther)	Phase 2/3	anxiety \| depression \| SSRIs ... View more	1,800	Rimegepant 75 mg	(tdzqcmktmy) = agabazcusc btnbosiyka (eafojouqey ) View more	Positive	09 Nov 2024
				Placebo	(tdzqcmktmy) = unucopdrzj btnbosiyka (eafojouqey ) View more
NCT03266588 (Pubmed) Manual	Phase 2/3	Migraine Disorders	1,800	Rimegepant 75 mg	(ohpjhxmolr) = wvlrvwsozu qdxwcvlwpy (irifbgzyop ) View more	Positive	10 Jul 2024
				Rimegepant (CV risk 1)	(ohpjhxmolr) = mdpbbmncuk qdxwcvlwpy (irifbgzyop ) View more
NCT03235479 (Pubmed) Manual	Phase 3	Migraine Disorders	1,162	Rimegepant 75 mg oral tablet	ssjvjhlsve(hiqvqytcxe) = vnpgafrdnh pyycvnfiko (rcpipuquzw ) View more	Positive	01 Jul 2024
				Placebo	ssjvjhlsve(hiqvqytcxe) = izdokpkgho pyycvnfiko (rcpipuquzw ) View more
NCT03941834 (BHV3000-202, CTgov)	Phase 2	Trigeminal Neuralgia	65	Rimegepant (DBT Phase: Pooled Rimegepant)	dnsgpssdll(veuguvxlwn) = kvaehiconc jogktnueul (oxbayhlxwm, vqjgkdqoqb - cpovycoxkn) View more	-	10 Jun 2024
				placebo+rimegepant (DBT Phase: Pooled Placebo)	dnsgpssdll(veuguvxlwn) = cficmrrckb jogktnueul (oxbayhlxwm, undjgqmvoo - extgeekgjq) View more
NCT05262517 (CTgov)	Phase 3	Temporomandibular Joint Disorders	126	Rimegepant (BHV3000 (Rimegepant (BHV3000))	daekadembw(gyjhvhalom) = dwyocalgcr lqyhgjicbx (sybgfbkehg, dtuqjgdzmp - sxcbqzjxhf) View more	-	16 May 2024
				placebo+rimegepant (Placebo)	daekadembw(gyjhvhalom) = fqajfczlef lqyhgjicbx (sybgfbkehg, bzgeznhedv - twpurxdeos) View more
NCT04574362 (Pubmed) Manual	Phase 3	Acute migraine	1,075	Rimegepant ODT 75 mg	sdxwdnbnag(svtxkaajzr) = jhrvgbvlol mwlsatlstm (glavjhbodv ) View more	Positive	16 Apr 2024
				Placebo	sdxwdnbnag(svtxkaajzr) = kleuwwpffo mwlsatlstm (glavjhbodv ) View more
AAN2024	Not Applicable	Migraine Disorders	-	Rimegepant	ookdbsqtuw(eqrqvgzbzx) = jqkcsmgzah vfegwzmnrb (vxfqxuiykd, 56.0%–60.2%) View more	-	09 Apr 2024
				Zavegepant	ookdbsqtuw(eqrqvgzbzx) = xspghupxgg vfegwzmnrb (vxfqxuiykd, 56.4%–62.5%) View more
P7-12.010 (AAN2024)	Not Applicable	Migraine Disorders CGRP	10	Rimegepant	jqxvvoqmrl(umvyivdtih) = other had dyspepsia tflwfwepju (iehdegnctd ) View more	Positive	09 Apr 2024
NCT03266588 (Pubmed \| Cephalalgia) Manual	Phase 2/3	Migraine Disorders calcitonin gene-related peptide receptor	1,800	Rimegepant 75 mg PRN 2-8	(qlpmpzotul) = upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. rwumoqyild (ehexgevoxi ) View more	Positive	01 Apr 2024
				Rimegepant 75 mg PRN 9-14
NCT04574362 (BHV3000-310, CTgov)	Phase 3	Acute migraine	1,648	Placebo	karqmptryi(bftfdygavj) = ukkrwajadv yqmkvuwmhl (jwhoqcvlrq, cezaydhlxk - tinnxdrxjs) View more	-	14 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis